EHP® is not a single intervention. It is a combined extracorporeal procedure that integrates three distinct mechanisms: haemoperfusion, hemo-hyperthermia, and oxygenation, delivered simultaneously during a single treatment session. Blood is drawn from the patient, passed through a specialised external circuit where all three processes occur, and returned to the body.

Each component has a different function:

• Haemoperfusion passes the blood through a specialised adsorbent cartridge that selectively removes toxins, inflammatory mediators, and tumour-associated substances from the bloodstream, reducing the systemic burden that both the cancer and its treatment generate
• Hemo-hyperthermia heats the blood to a controlled range of 40°C to 42°C as it moves through the circuit. This is distinct from whole-body hyperthermia, which carries far greater physiological risk. At this temperature range, cancer cells,  which are less heat-tolerant than healthy cells, are weakened and rendered more susceptible to conventional treatments such as chemotherapy and radiotherapy
• Oxygenation elevates tissue oxygen saturation substantially. Many tumour cells exploit low-oxygen environments to resist treatment and promote aggressive behaviour. Restoring oxygen availability disrupts this, supports cellular repair in surrounding healthy tissue, and promotes neovascularisation

The combination of these three processes, delivered simultaneously within a single circuit, is what distinguishes EHP® from other supportive approaches.

Cancer is not one disease. It is hundreds of biologically distinct conditions that share one feature: abnormal cells that evade the body's normal controls. The treatments designed to stop them, chemotherapy, radiotherapy, immunotherapy, and targeted therapies, are often effective. They are also, for many patients, incomplete.

Several biological realities limit what conventional oncology can achieve alone:

• Tumour immune evasion: Cancer cells actively suppress immune detection by releasing immunosuppressive signalling molecules into the bloodstream, creating an environment that prevents the immune system from mounting an effective response
• Tumour hypoxia: Low-oxygen conditions within and around tumours promote resistance to radiotherapy, stimulate metastatic spread, and support aggressive cell behaviour
• Systemic inflammatory and toxic burden: Both the cancer itself and its treatment generate significant inflammatory mediators and toxic metabolites that accumulate in the bloodstream, contributing to fatigue, organ stress, and reduced treatment tolerability
• Treatment resistance: Cancer cells can develop resistance to chemotherapy or targeted agents over time, limiting their long-term effectiveness
• Immune suppression from treatment: Many standard therapies suppress the immune system precisely when the body most needs it to be active

EHP® does not replace conventional oncological treatment. What it does is address several of these biological problems concurrently, clearing toxic and inflammatory burden, weakening cancer cells thermally, restoring oxygenation, and supporting immune function in ways that standard treatment alone cannot.

Supportive oncological care is essential. Managing pain, nausea, fatigue, and nutritional status during treatment directly affects a patient's ability to complete their regimen, but standard supportive care does not engage with tumour biology; it manages the consequences of cancer and its treatment rather than the conditions that allow the disease to persist.

EHP® does not replace any of these. It works alongside them, addressing systemic biological factors that standard supportive care does not reach.

The clinical relevance of EHP® in oncology emerges from how its three components interact with cancer biology at the cellular and systemic level:

• Thermal sensitisation of tumour cells: Cancer cells exposed to hemo-hyperthermia sustain heat-induced damage to membrane integrity and DNA repair mechanisms. This thermal stress makes them significantly more vulnerable to the cytotoxic effects of chemotherapy, a principle supported by published research into hyperthermia-based oncology. The key distinction from EHP® is that only the blood is heated, not the whole body, thereby avoiding the systemic risks associated with conventional hyperthermia approaches.
• Immune system restoration: Haemoperfusion removes circulating immunosuppressive factors released by tumours to evade immune detection. With these signals cleared from the bloodstream, the immune system is better positioned to recognise and respond to cancer cells.
• Disruption of tumour hypoxia: The oxygenation component directly counteracts the low-oxygen environment that many cancers create to resist radiotherapy and drive metastatic spread. Elevated tissue oxygen saturation also supports repair in the healthy tissue surrounding the tumour
• Reduction of pro-tumorigenic inflammation: Chronic tumour-driven inflammation, mediated by cytokines, actively promotes cancer progression and spread. Haemoperfusion removes these mediators from circulation, reducing the inflammatory microenvironment that sustains tumour growth.
• Detoxification support: Chemotherapy generates a significant toxic metabolite burden on the liver and kidneys. EHP® supports the clearance of these substances, which may reduce organ stress and improve a patient's capacity to tolerate and complete their conventional treatment schedule.

Important: EHP® is a supportive therapy. It is not a cure for cancer and does not replace conventional oncological treatment. Outcomes vary between individuals and depend on cancer type, stage, current treatment, and individual biological response. GS Medical Services is committed to providing an honest assessment of what this treatment may and may not offer each patient.

A structured EHP® programme is designed specifically for international and regional patients. Every step is coordinated by a dedicated team.

Step 1: Comprehensive Medical Review and Eligibility Assessment

Your journey begins with a thorough evaluation to determine whether EHP® is appropriate for your specific situation:

• Full review of your oncological history, current diagnosis, disease stage, and active treatment plan
• Assessment of current medications, laboratory findings, and cardiovascular status
• In-depth consultation with the medical team
• Honest, transparent assessment of whether you are a suitable candidate, including a direct answer if the evidence does not support treatment in your case

Step 2: Personalised Treatment Planning

If assessed as a suitable candidate, a treatment protocol is developed around your specific circumstances:

• Protocol tailored to your cancer type, current treatment regimen, overall health status, and functional capacity
• Clear explanation of the procedure, session frequency, and realistic outcome expectations
• Transparent discussion of how EHP® fits alongside your existing oncological care, including timing relative to chemotherapy cycles
• Comprehensive logistics support, including travel arrangements and accommodation guidance for international patients

Step 3: The EHP® Procedure

Treatment is conducted by experienced, licensed physicians at the authorised EHP® centres:

• Blood is accessed via standard venous access; no surgical intervention is required
• The haemoperfusion, hemo-hyperthermia, and oxygenation components run simultaneously through a single extracorporeal circuit
• On an outpatient basis, most patients return to their accommodation the same day
• Continuous vital sign monitoring throughout, with physician supervision at all times
• Each session typically takes 3-5 hours, including preparation and post-procedure observation

Step 4: Structured Follow-Up and Progress Monitoring

Your care continues well beyond the treatment session:

• Remote follow-up via secure telemedicine, no need to return to Germany for routine reviews
• Progress evaluation in coordination with your existing oncology team, using available imaging and laboratory markers
• Personalised guidance on integrating EHP® with your ongoing conventional treatment schedule
• Long-term monitoring to assess the clinical impact of treatment over time
• Direct access to the medical team throughout, for questions or concerns as they arise

EHP® is not appropriate for every cancer patient. Based on current clinical evidence, those most likely to benefit typically share the following profile:

• Confirmed cancer diagnosis, including patients with metastatic or advanced-stage disease
• Currently undergoing or planning conventional oncological treatment, EHP® is designed to work alongside standard care
• Seeking to improve the effectiveness or tolerability of chemotherapy or radiotherapy
• Experiencing significant treatment-related fatigue or toxic burden that is limiting their capacity to sustain conventional treatment
• Adequate cardiovascular function, EHP® involves extracorporeal blood processing and requires the circulation to tolerate the procedure safely
• No active uncontrolled bleeding, critical anaemia, or severe cardiac insufficiency
• Realistic expectations and a clear understanding that EHP® is a supportive rather than curative intervention
• Willingness to remain actively engaged with their conventional oncology team throughout the process

Suitability is assessed individually. If your situation is unclear, the initial consultation is the appropriate place to find out.

Based on clinical outcomes and published research into the component mechanisms, EHP® as a supportive cancer therapy may offer the following benefits. Outcomes are not guaranteed and vary from individual to individual.

• Increased tumour cell susceptibility to conventional treatment: Thermal sensitisation through hemo-hyperthermia makes cancer cells more vulnerable to chemotherapy and radiotherapy administered in conjunction with EHP®.
• Improved immune engagement: Removal of immunosuppressive tumour-associated factors may allow the immune system to respond more effectively to cancer cells.
• Better treatment tolerability: Detoxification support may reduce the cumulative toxic load of chemotherapy, helping patients sustain their treatment schedules with fewer dose reductions or interruptions.
• Reduced systemic inflammatory burden: Clearance of pro-tumorigenic cytokines and inflammatory mediators may slow cancer-driven inflammation and its downstream effects.
• Disruption of tumour hypoxia: Enhanced tissue oxygenation reduces the low-oxygen conditions that many cancers exploit for growth and treatment resistance.
• Reduced treatment-related fatigue: Some patients report meaningful improvements in energy levels associated with reduced toxic and inflammatory burden.
• Improved quality of life during treatment: Broader functional improvements, better sleep, reduced nausea, and greater physical capacity are reported alongside disease-specific responses.

Clinical data have documented favourable outcomes in patients with metastatic cancer who received EHP® alongside conventional treatment. The field continues to develop, and GS Medical Services works exclusively with clinics that follow evidence-informed protocols.

EHP® has been administered to patients with a range of complex conditions, and its safety profile is well-documented within that clinical context. Like any extracorporeal blood procedure, it carries risks that will be discussed in full during your consultation.

Common side effects, typically mild and temporary:

• Fatigue in the 24 to 48 hours following a session, which generally resolves without intervention
• Mild headache or lightheadedness during or shortly after treatment
• Minor discomfort at the venous access site
• A transient drop in blood pressure during the procedure is managed by the supervising physician

Rare but serious complications:

• Haemodynamic instability, patients with compromised cardiovascular function require careful pre-procedure assessment and may not be suitable candidates
• Infection at the access site is uncommon when clinical protocols are properly followed
• Adverse reaction to components of the extracorporeal circuit
• Clotting within the circuit was managed with anticoagulation protocols during the procedure

EHP® is contraindicated in patients with severe active bleeding, critical anaemia, or significant cardiac insufficiency. These are identified and ruled out during pre-procedure screening.
Post-Treatment Guidance: All patients receive comprehensive post-treatment instructions, including rest and hydration recommendations, guidance on resuming conventional treatment schedules, warning signs requiring immediate attention, and dietary advice to support recovery and optimise the detoxification effects of the procedure.

Accessing a specialised procedure like EHP® involves clinical, logistical, and coordination challenges that are difficult to navigate independently. GS Medical Services exists to manage that complexity. Finding a coordination partner who is honest about what a treatment can and cannot do makes a genuine difference. Here is what we offer:

• Personalised Treatment Plans: Cancer presentations vary too widely for a standard approach to make sense. Your EHP® protocol is built around your specific diagnosis, current treatment regimen, disease stage, and what is actually achievable given your circumstances.
• Compassionate & Expert Care: Patients exploring supportive cancer therapy have usually been through a great deal already. Our physicians and coordinators know that. Consultations are direct, unhurried, and honest, including when the answer is that EHP® is not the right fit for a particular patient.
• International Patient Support: Scheduling, medical documentation, clinic communication, and accommodation guidance, all coordinated to keep your focus on treatment, not logistics.
• Transparency & Honest Guidance: EHP® has a specific evidence base and a specific patient profile it suits. We are clear about both. If your case does not meet the criteria, we say so at the consultation, not after you have committed time and money.
• Continuity of Care: Structured telemedicine follow-up, coordination with your oncology team, and ongoing access to the medical team continue well after you return home.

If you or a family member is living with cancer and seeking to strengthen the effectiveness of conventional treatment, a comprehensive medical evaluation is a sensible next step. You may consult Dr. Med. Gerhard Siebenhüner for an expert assessment and personalised guidance on whether EHP® is appropriate for your situation.

Your initial consultation covers:

• A confidential review of your oncological records, current treatment plan, and clinical history
• A straight assessment of whether EHP® is appropriate for your specific cancer type, stage, and overall health
• A grounded conversation about what improvement may look like, what the risks are, and what outcomes are realistically possible alongside your existing treatment
• A full walkthrough of the procedure, session frequency, and what travelling to Frankfurt involves practically
• Complete pricing breakdown upfront, with no costs that appear later
• As much time as you need to ask questions

Proceeding after the consultation is entirely your decision. What we can offer is enough information to make a considered choice, and the space to make it without pressure.

How does  EHP® differ from standard hyperthermia? 

Standard hyperthermia heats the entire body, which carries a significant physiological risk. EHP® heats only the blood as it passes through the external circuit, delivering thermal effects on cancer cells without exposing the whole body to heat stress.

Is EHP® a replacement for chemotherapy or radiotherapy? 

No. EHP® is a supportive therapy designed to complement conventional oncological treatment, not replace it. Its value lies in making standard treatment more effective and more tolerable, not in functioning as a standalone cancer treatment.

How long does each EHP® session take? 

Each session typically takes 3-5 hours, including preparation and post-procedure monitoring. Most patients return to their accommodation the same day.

Can EHP® be used alongside active chemotherapy or immunotherapy? 

In most cases, yes. The timing of EHP® relative to chemotherapy cycles is planned carefully to maximise the thermal sensitisation effect and minimise any interaction with active treatment. Your oncology team is involved in this coordination.

How is EHP® regulated in Germany?

In Germany, EHP® is classified as a medical procedure and must comply with national medical and safety standards. Treatment is performed exclusively at the authorised centre, under qualified physician supervision, following an individual medical evaluation.

How much does EHP® cost? 

Costs vary depending on the number of sessions required and the specifics of your treatment protocol. Transparent, itemised pricing is provided following your medical assessment.

The information provided on this page is for educational and informational purposes only and should not be construed as medical advice. EHP® outcomes vary between individuals, and treatment may not be suitable for everyone. EHP® is a supportive therapy and is not a cure for cancer. Always consult a qualified medical professional, including your oncologist, before making decisions about your health.